Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.

Barrett PN, Portsmouth D, Ehrlich HJ.

Expert Rev Vaccines. 2013 Apr;12(4):395-413. doi: 10.1586/erv.13.21. Review.

PMID:
23560920
2.

Clinical vaccine development for H5N1 influenza.

Clegg CH, Rininger JA, Baldwin SL.

Expert Rev Vaccines. 2013 Jul;12(7):767-77. doi: 10.1586/14760584.2013.811178. Review.

PMID:
23885822
4.

Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.

Rudenko L, Isakova-Sivak I.

Expert Rev Vaccines. 2015 Mar;14(3):395-412. doi: 10.1586/14760584.2015.979159. Epub 2015 Jan 2. Review.

PMID:
25555687
5.

Vaccines against epidemic and pandemic influenza.

Hoelscher M, Gangappa S, Zhong W, Jayashankar L, Sambhara S.

Expert Opin Drug Deliv. 2008 Oct;5(10):1139-57. doi: 10.1517/17425247.5.10.1139 . Review. Erratum in: Expert Opin Drug Deliv. 2009 Feb;6(2):209.

PMID:
18817518
6.

Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.

Chan CY, Tambyah PA.

Expert Rev Vaccines. 2012 Jul;11(7):759-73. doi: 10.1586/erv.12.55. Review.

PMID:
22913252
7.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
8.

Clinical development of a Vero cell culture-derived seasonal influenza vaccine.

Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13.

PMID:
22172502
9.

Pandemic H5N1 influenza vaccine development: an update.

El Sahly HM, Keitel WA.

Expert Rev Vaccines. 2008 Mar;7(2):241-7. doi: 10.1586/14760584.7.2.241. Review.

PMID:
18324892
10.

Continuous cell lines as a production system for influenza vaccines.

Genzel Y, Reichl U.

Expert Rev Vaccines. 2009 Dec;8(12):1681-92. doi: 10.1586/erv.09.128. Review.

PMID:
19943763
11.

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.

Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.

PMID:
22192847
12.

A cell-based backup to speed up pandemic influenza vaccine production.

Lee MS, Hu AY.

Trends Microbiol. 2012 Mar;20(3):103-5. doi: 10.1016/j.tim.2011.12.002. Epub 2012 Jan 16.

PMID:
22257962
13.

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.

Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ.

Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12.

PMID:
22080174
14.

Cell-culture-derived influenza vaccine production.

Glezen WP.

Lancet. 2011 Feb 26;377(9767):698-700. doi: 10.1016/S0140-6736(11)60174-8. Epub 2011 Feb 15. No abstract available.

PMID:
21329970
15.

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN.

Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8.

PMID:
22884662
16.

Emulsion-based adjuvants for influenza vaccines.

Vogel FR, Caillet C, Kusters IC, Haensler J.

Expert Rev Vaccines. 2009 Apr;8(4):483-92. doi: 10.1586/erv.09.5. Review.

PMID:
19348563
17.

Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.

Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS.

Vaccine. 2011 Oct 13;29(44):7579-86. doi: 10.1016/j.vaccine.2011.08.031. Epub 2011 Aug 19.

PMID:
21856358
18.

Aflunov(®): a prepandemic influenza vaccine.

Gasparini R, Amicizia D, Lai PL, Panatto D.

Expert Rev Vaccines. 2012 Feb;11(2):145-57. doi: 10.1586/erv.11.170. Review.

PMID:
22309663
19.

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

Howard MK, Kistner O, Barrett PN.

Biol Chem. 2008 May;389(5):569-77.

PMID:
18953724
20.

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P.

J Infect Dis. 2009 Oct 1;200(7):1113-8. doi: 10.1086/605608.

PMID:
19712040

Supplemental Content

Support Center